Santa Mª Del Camí, Baleares, Spain
A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR)
Phase
3Span
300 weeksSponsor
Chiesi Farmaceutici S.p.A.Pendik
Recruiting
Results of Safety Guidewire Use in Ureteroscopic Stone Surgery
Phase
N/ASpan
292 weeksSponsor
Marmara UniversityPendik
Recruiting
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
To Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients with Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis.
Phase
3Span
365 weeksSponsor
Gilead SciencesPendik
Recruiting
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Phase
3Span
362 weeksSponsor
Eli Lilly and CompanyPendik, İstanbul
Recruiting
1-4 of 4